[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:tuberculosis-infection":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Tuberculosis Infection",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT03474029","Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI",[11],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:18:15.214990Z","2026-05-05T02:43:26.742542Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05022862","Economic Incentives and vDOT for Latent Tuberculosis Infection",[],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.990605Z",[],[]]